EP1767217A1 - Wirkstoff zur förderung der erholung von einer dysfunktion nach ausbruch einer erkrankung des zentralen nervensystems - Google Patents

Wirkstoff zur förderung der erholung von einer dysfunktion nach ausbruch einer erkrankung des zentralen nervensystems Download PDF

Info

Publication number
EP1767217A1
EP1767217A1 EP05765630A EP05765630A EP1767217A1 EP 1767217 A1 EP1767217 A1 EP 1767217A1 EP 05765630 A EP05765630 A EP 05765630A EP 05765630 A EP05765630 A EP 05765630A EP 1767217 A1 EP1767217 A1 EP 1767217A1
Authority
EP
European Patent Office
Prior art keywords
agent
dysfunction
promoting
onset
recovery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05765630A
Other languages
English (en)
French (fr)
Inventor
Sachiko Astellas Pharma Inc. YATSUGI
Masayasu Astellas Pharma Inc. TAKAHASHI
Shinichi Astellas Pharma Inc. YATSUGI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of EP1767217A1 publication Critical patent/EP1767217A1/de
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a pharmaceutical drug, in particular, an agent for promoting the recovery from dysfunction after the onset of a central neurological disease and an agent for enhancing and/or promoting the effect of rehabilitation for functional recovery after the onset of a central neurological disease.
  • Many patients with central neurological disease are targets of rehabilitation medicine in Japan.
  • These diseases include a variety of disorders: motor dysfunctions such as mobility disorders of the extremities and gait dysfunction, neurological disorders such as hemiplegia, psychiatric disorders such as cognitive impairment and depressive state, and the like.
  • Drug therapy and rehabilitation for functional recovery are conducted, depending on the progress of a disease condition and the severity of disorder.
  • the ratio of stroke patients to the patients who are given rehabilitation medicine is highest.
  • stroke accounts for approximately 30% of the causes for becoming bedridden and the number of patients suffering from its sequela is estimated to be approximately 1.7 million ( Guidelines for the Management of Stroke in Japan, 2004 (The Japan Stroke Society )).
  • Compound A has the effect of enhancing serotonin neurotransmission based on the serotonin reuptake inhibitory activity as well as the effect of enhancing norepinephrine neurotransmission based on the 5-HT2A receptor antagonism, and its activity is comparable to that of venlafaxine, a serotonin-norepinephrine reuptake inhibitor, described below (Non-patent Document 1 and Non-patent Document 2). That is to say, Compound A is a compound that has the effect of enhancing both serotonin and norepinephrine neurotransmissions.
  • Patent Document 1 discloses that Compound A is useful as a therapeutic drug for secondary symptoms of a cerebrovascular disorder, such as a decrease of spontaneity and depressive mood, and as an agent for improving cerebral function due to its blood viscosity improving effect and antihypoxic effect.
  • a cerebrovascular disorder such as a decrease of spontaneity and depressive mood
  • an agent for improving cerebral function due to its blood viscosity improving effect and antihypoxic effect there is neither suggestion nor specific disclosure on the effect of promoting recovery from dysfunction, including motor dysfunction due to a central neurological disease, or the effect of enhancing and/or promoting the effect of rehabilitation for functional recovery.
  • Non-patent Document 3 and Non-patent Document 7 enhancement of norepinephrine neurotransmission promotes the recovery from dysfunction after brain injury
  • D-amphetamine a monoamine release promoter
  • Fluoxetine a selective serotonin reuptake inhibitor (SSRI)
  • SSRI selective serotonin reuptake inhibitor
  • D-amphetamine causes adverse drug reactions such as drug dependence, an excitatory effect, and effects on the circulatory system, and the effect of fluoxetine for promoting functional recovery is insufficient as compared with that of D-amphetamine (Non-patent Document 9). Accordingly, drugs that are safer and have excellent efficacy have been desired.
  • Patent Document 1 International Patent Publication WO94/18182 Pamphlet
  • Non-patent Document 1 Eur. J. Pharmacol. 395(1), 31-36, 2000
  • Non-patent Document 2 J. Pharmacol. Exp. Ther. 302 (3), 983-991, 2002
  • Non-patent Document 3 Science 217, 855-857,1982
  • Non-patent Document 4 Stroke 29, 2381-2395, 1998
  • Non-patent Document 5 Ann. Neurol. 23, 94-97, 1988
  • Non-patent Document 6 Stroke 26,2254-2259, 1995
  • Non-patent Document 7 Am. J. Phys. Med. Rehabil. 72, 286-293, 1993
  • Non-patent Document 8 Stroke 27, 1211-1214, 1996
  • Non-patent Document 9 Am. J. Phys. Med. Rehabil. 73, 76-83, 1994
  • An object of the present invention is to provide a pharmaceutical drug useful as an agent for promoting the recovery from dysfunction after the onset of a central neurological disease and an agent for enhancing and/or promoting the effect of rehabilitation for functional recovery after the onset of a central neurological disease.
  • an object of the present invention is to provide a pharmaceutical drug superior to conventionally known drugs, fluoxetine, desipramine, and D-amphetamine, in terms of the above promotion and/or enhancement effects or reduction in adverse drug reactions.
  • the present inventors further studied drugs that promote the recovery from dysfunction due to a central neurological disease, and as the result confirmed that compounds that simultaneously and selectively enhance serotonin neurotransmission and norepinephrine neurotransmission, especially Compound A, have an excellent effect of promoting recovery of motor functions, and completed the present invention.
  • the present invention relates to an agent for promoting the recovery from dysfunction after the onset of a central neurological disease such as stroke, brain injury, neurodegenerative disease, and spinal cord injury, comprising a compound that simultaneously and selectively enhances serotonin neurotransmission and norepinephrine neurotransmission as an active ingredient; and an agent for enhancing and/or promoting the effect of rehabilitation for functional recovery after the onset of a central neurological disease comprising a compound that simultaneously and selectively enhances serotonin neurotransmission and norepinephrine neurotransmission as an active ingredient.
  • a central neurological disease such as stroke, brain injury, neurodegenerative disease, and spinal cord injury
  • an agent for enhancing and/or promoting the effect of rehabilitation for functional recovery after the onset of a central neurological disease comprising a compound that simultaneously and selectively enhances serotonin neurotransmission and norepinephrine neurotransmission as an active ingredient.
  • the present invention is useful for providing an excellent agent for promoting the recovery from dysfunction due to a central neurological disease and an agent for enhancing and/or promoting rehabilitation for functional recovery.
  • the pharmaceutical drug of the present invention is useful as a safe drug free from adverse drug reactions due to an anticholinergic effect, such as dry mouth, constipation, dysuria, and blurred vision, or drug dependence.
  • Compound A is superior to conventionally known drugs, fluoxetine, desipramine, and D-amphetamine, in terms of the above promotion and/or enhancement effect or reduction in adverse drug reactions.
  • Compound A has a protective effect on mitochondrial dysfunction and affinity to sigma receptors, thus has an inhibitory effect on cell death due to stroke and the effect of enhancing neurite outgrowth, and is useful as a therapeutic agent of the present invention.
  • the present invention will be described in more detail.
  • the "compound that simultaneously and selectively enhances serotonin neurotransmission and norepinephrine neurotransmission” means a compound that has an effect of simultaneously enhancing both serotonin neurotransmission and norepinephrine neurotransmission through uptake inhibition or release promotion of serotonin and norepinephrine.
  • neither compounds that selectively enhance serotonin neurotransmission (for example, fluoxetine) nor compounds that selectively enhance norepinephrine neurotransmission (for example, desipramine) are included in the active ingredient of the present invention.
  • the "compound that simultaneously and selectively enhances serotonin neurotransmission and norepinephrine neurotransmission” does not include compounds that enhance neurotransmission via dopamine, a kind of monoamine.
  • conventionally known D-amphetamine is not included in the active ingredient of the present invention, since it promotes release of monoamines, but it is not a compound that simultaneously and selectively enhances serotonin neurotransmission and norepinephrine neurotransmission.
  • the active ingredient of the present invention includes, specifically SNRI and Compound A, and Compound A is particularly preferred.
  • the "SNRI” is a drug that has selective serotonin and norepinephrine uptake inhibitory effects, specifically including milnacipran (Asahi Kasei Corporation), venlafaxine (Wyeth), duloxetine (Lilly), F-98214-TA (FAES Farma), and the like.
  • milnacipran, venlafaxine, and duloxetine are known as "antidepressants,” they are not recognized as the agent of the present invention for promoting the recovery from dysfunction after the onset of a central neurological disease or an agent for enhancing and/or promoting the effect of rehabilitation for functional recovery after the onset of a central neurological disease.
  • the "dysfunction after the onset of a central neurological disease” means motor dysfunction, sensory function disorder, speech function disorder, and the like caused by disorder of nervous functions controlled by the sites damaged by stroke, brain injury, neurodegenerative diseases, spinal cord injury, and the like. It does not include psychiatric disturbance such as depressive symptom or cognitive impairment such as dementia.
  • the dysfunction to which the present invention is preferably applied is motor dysfunction.
  • the "stroke” is classified into hemorrhagic and non-hemorrhagic.
  • Examples of the hemorrhagic stroke include cerebral hemorrhage, subarachnoid hemorrhage, and intracranial hemorrhage secondary to cerebral arterial malformation, while examples of the non-hemorrhagic stroke include cerebral infarction.
  • the "brain injury” refers to a condition in which the brain is traumatically damaged by injury caused in a traffic accident or the like, including brain contusion, epidural hematoma, subdural hematoma, intracerebral hematoma, diffuse axonal injury, and the like.
  • the "spinal cord injury” refers to a condition in which the spinal cord receives compression/detrition due to a vertebral fracture or dislocation to cause dysfunction.
  • the "neurodegenerative disease” refers to a syndrome with chronic and progressive death of neuronal cells belonging to a particular functional system. Examples thereof include Parkinson disease, spinocerebellar degeneration, multiple system atrophy, amyotrophic lateral sclerosis, and the like.
  • the "motor dysfunction” refers to a condition with which performing voluntary movements is difficult, impossible, or not smooth, and it means motor paralysis and ataxia. Specifically it is disorder of skill movement, Babinski sign, spastic paralysis, spasticity (chronic phase), increased deep tendon reflex (chronic phase), muscle rigidity, bradypragia, involuntary movement (tremors, choreic movement, athetosis, dystonia, etc.), ataxia (extremities and trunk), speech function disorder, or eating disorder/dysphagia.
  • the present invention is preferably applied to gait dysfunction and upper extremity function disorder.
  • the “sensory function disorder” refers to a condition in which cerebral disorder disables correct recognition of superficial sensation such as tactile sensation, baresthesia, and thermoesthesia; deep sensation such as position sensation and palleshesia; combined sensation such as two-point discrimination and graphesthesia; or the like. It is classified according to the severity into anesthesia (sensory extinction), hypesthesia (sensory blunting), hyperesthesia, and dysaesthesia (paresthesia). It also includes sensory function disorders characterized by the site of occurrence, such as dysethesia of half of the body, superficial sensation disorder, and whole sensation disorder.
  • the "speech function disorder” refers to aphasia characterized by decrease of ability in terms of language, such as listening, reading, speaking and writing words caused by a damage in the region controlling a language function; and dysarthria characterized by symptoms such as dysphonia and phonation disorder due to paralysis of the phonic and speech organs such as the lips, tongue and vocal band or disadaptation of movement (ataxia).
  • the present invention is preferably applied to dysarthria due to motor dysfunction.
  • the "promotion of the recovery from dysfunction” means recovery from the above dysfunction earlier and to a higher level for purposes of shortening of a hospitalization period, and promoting early independence and improvement of quality of life (QOL), and the like after the onset.
  • the application of the present invention preferably relates to motor dysfunction due to stroke, brain injury, neurodegenerative disease, or spinal cord injury, more preferably to gait dysfunction and upper extremity dysfunction after stroke.
  • the "rehabilitation for functional recovery” means rehabilitation for recovery of motor functions, such as muscle-strengthening exercise, range-of-motion exercise of hand fingers, knees and the like, motion exercise such as walking; rehabilitation for recovery of language functions; rehabilitation for recovery of cognitive functions, and the like that are conducted in the acute phase, recovery phase, and maintenance phase according to the time after onset of a central neurological disease and the condition of a patient.
  • the present invention is preferably applied to rehabilitation for recovery of motor functions.
  • the "enhancing the effect of rehabilitation for functional recovery” means recovery of a function to a higher level and further alleviation of a disorder as compared with the case of conducting rehabilitation alone.
  • the "promoting the effect of rehabilitation for functional recovery” means promotion of functional recovery in a shorter period as compared with that conducted by rehabilitation alone.
  • (S)-2-[[(7-Fluoro-4-indanyl)oxy]methyl]morpholine and its pharmaceutically acceptable salts can be readily obtained by the manufacturing method described in Patent Document 1 or manufacturing methods similar thereto. Milnacipran can be readily obtained by the method described in US Patent US4478836 , venlafaxine by the method described in British Patent No. GB2227743 , duloxetine by the method described in US Patent US5362886 , and F-98214-TA by the method described in Journal of Medicinal Chemistry (2003), 46(25), 5512-5532 or the methods similar thereto.
  • Compound A can form salts with acids besides hydrochloride. Such salts are included in the present invention as long as they are pharmaceutically acceptable salts.
  • examples of the acids include inorganic acids such as hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, and phosphoric acid; and organic acids such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, aspartic acid, and glutamic acid.
  • Compound A includes various hydrates, solvates, and polymorphism of its free form and pharmaceutically acceptable salts.
  • the preparation of the present invention can be prepared using carriers for pharmaceuticals, excipients and the like usually used in the art by the methods usually used.
  • Administration may be oral administration using tablets, pills, capsules, granules, powder, liquid, and the like, or parental administration using injections such as intraarticular, intravenous, intramuscular injections, suppository, eye drops, eye ointment, percutaneous liquid, ointment, percutaneous patch, transmucosal liquid, transmucosal patch, inhalant, and the like.
  • the form of the solid composition for oral administration according to the present invention includes tablet, powder, granule, and the like.
  • one or more active ingredients are mixed with at least one inert diluent, for example, lactose, mannitol, glucose, hydroxypropylcellulose, microcrystalline cellulose, starch, polyvinylpyrrolidone, and/or magnesium aluminate metasilicate.
  • the composition may contain, according to conventional manners, additives other than the inert diluents exemplified by lubricants such as magnesium stearate, disintegrants such as cellulose calcium gluconate, stabilizers, and solubilizing aids.
  • Tablets and pills may be coated with sugar, such as sucrose, gelatin, hydroxypropylcellulose, hydroxypropylmethylcellulose phthalate and the like, or a film of a gastric or enteric substance.
  • the form of the liquid composition for oral administration includes pharmaceutically acceptable emulsion, solution, suspension, syrup, elixir, or the like, and the liquid composition contains a generally used inert diluent, for example, purified water or ethanol.
  • the liquid composition may contain aids such as solubilizing agents, moisturizers, and suspending agents, sweeteners, flavors, aromatic substances, or preservatives in addition to the inert diluent.
  • the injection for parenteral administration contains a sterile aqueous or non-aqueous solvent, suspending medium, or emulsifying medium.
  • the aqueous solvent or suspending medium includes distilled water for injection and physiological saline.
  • the non-aqueous solvent or suspending medium is exemplified by propylene glycol, polyethylene glycol, vegetable oils such as olive oil, alcohols such as ethanol, Polysolvate 80 (the name in the Japanese Pharmacopeia), and the like. These compositions may further contain tonicity agents, preservatives, moisturizers, emulsifiers, dispersing agents, stabilizers, or solubilizing aids.
  • compositions are sterilized, for example, by filtration through a bacteria-retentive filter, by addition of a bactericide, or by irradiation.
  • a sterile solid composition may be prepared and, prior to use, dissolved or suspended in sterile water or a sterile solvent for injection.
  • the transmucosal preparations such as a transnasal preparation may be solid, liquid or semi-liquid and can be manufactured according to conventionally known methods. For example, publicly known pH adjusters, preservatives, thickeners, and excipients may be added as appropriate and the composition is formed into solid, liquid or semi-liquid.
  • the transnasal preparation is administered through an ordinary spray apparatus, a nasal spray, a tube, an insert for the nasal cavity, or the like.
  • the drug used in the present invention is administered to patients having dysfunction after the onset of a central neurological disease, preferably to patients immediately after to within 6 months after the onset, over the period of rehabilitation for functional recovery (1 month to 1 year at the maximum, preferably 3 to 6 months).
  • An appropriate daily dose for oral administration is usually about 0.01 to 1000 mg, preferably 0.1 to 300 mg/kg, further preferably 0.1 to 100 mg, and the daily dose is administered once or divided into 2 to 4 portions daily over the period of rehabilitation for functional recovery.
  • an appropriate daily dose is about 0.001 to 100 mg/kg body weight and the daily dose is administered once or divided into several portions daily.
  • a dose may be determined individually according to symptoms, age, sex, and the like.
  • D-amphetamine was administered intraperitoneally 60 minutes prior to the walking function tests from 3 days to 2 weeks after preparation of cerebral infarction.
  • Physiological saline in the same volume was administered to the control group.
  • the corresponding pre-drug values were subtracted, and statistical analysis were performed by two-way repeated-measures analysis of variance. When a significant difference was observed, a multiple comparison was conducted. The results are shown in Figs. 1 to 3. As shown in Fig.
  • cerebral infarction was prepared as in Example 1.
  • Compound A was administered orally at a dose of 5 mg/kg five times per week from the next week following cerebral infarction preparation to week 6.
  • D-amphetamine was administered intraperitoneally at a dose of 1.5 mg/kg twice per week from the next week following cerebral infarction preparation to week 6.
  • Distilled water or physiological saline in the same amount was administered to the control group.
  • the test was conducted 60 minutes after drug administration. Drug efficacy was analyzed by the Dunnett's multiple comparison. The results are shown in Fig. 4. As shown in Fig.
  • the forepaw dysfunction is compared by using the number of displaced pellets (a) and the number of eaten pellets (b) in the staircase test as indices, indicating that a significant improvement effect was observed in the Compound A group as compared with the control group (*:p ⁇ 0.05, **: p ⁇ 0.01 vs. vehicle). Although a tendency toward improvement was observed in the D-amphetamine group as compared with the control group, the effect was not significant. Accordingly, the above test shows that Compound A has a promoting effect on recovery from forepaw dysfunction caused by stroke superior to that of D-amphetamine.
  • Fig. 6 Male spontaneous hypertension rats (Hoshino Laboratory Animals) weighing 240 to 275 g were used. After a cannula was inserted into the common carotid artery, heart rates were monitored. Compound A or D-amphetamine was administered orally or intraperitoneally, respectively, and the heart rates were recorded until 4 hours after administration. For the control group, physiological saline was administered intraperitoneally and the measurement was similarly conducted. Statistical analysis was conducted by one-way repeated-measures analysis of variance. When a significant difference was observed, a multiple comparison by the two-way Dunnet method was applied. The results are shown in Fig. 6. As shown in Fig.
  • Compound A exhibited an improvement effect better than that of fluoxetine in the beam-walking test and the foot-fault test. Accordingly, Compound A is more useful than fluoxetine as an agent for promoting the recovery from dysfunction after the onset of a central neurological disease and an agent for enhancing and/or promoting the effect of rehabilitation for functional recovery after the onset of a central neurological disease.
  • Compound A is an agent for promoting the recovery from dysfunction after the onset of a central neurological disease and an agent for enhancing and/or promoting the effect of rehabilitation for functional recovery after the onset of a central neurological disease, which has a wider safety range than D-amphetamine and has no adverse drug reaction at the dose exhibiting drug efficacy.
  • the present invention can be applied as a drug, particularly an agent for promoting the recovery from dysfunction after the onset of a central neurological disease and an agent for enhancing and/or promoting the effect of rehabilitation for functional recovery after the onset of a central neurological disease.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP05765630A 2004-07-14 2005-07-13 Wirkstoff zur förderung der erholung von einer dysfunktion nach ausbruch einer erkrankung des zentralen nervensystems Withdrawn EP1767217A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004207234 2004-07-14
PCT/JP2005/012895 WO2006006617A1 (ja) 2004-07-14 2005-07-13 中枢神経疾患発症後の機能障害の回復促進剤

Publications (1)

Publication Number Publication Date
EP1767217A1 true EP1767217A1 (de) 2007-03-28

Family

ID=35783954

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05765630A Withdrawn EP1767217A1 (de) 2004-07-14 2005-07-13 Wirkstoff zur förderung der erholung von einer dysfunktion nach ausbruch einer erkrankung des zentralen nervensystems

Country Status (12)

Country Link
US (1) US20070259865A1 (de)
EP (1) EP1767217A1 (de)
JP (1) JPWO2006006617A1 (de)
CN (1) CN1984681A (de)
AU (1) AU2005260955A1 (de)
BR (1) BRPI0513222A (de)
CA (1) CA2573611A1 (de)
IL (1) IL180379A0 (de)
NO (1) NO20070831L (de)
RU (1) RU2007105494A (de)
WO (1) WO2006006617A1 (de)
ZA (1) ZA200700711B (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007051090A1 (de) * 2007-06-28 2009-01-08 Charité - Universitätsmedizin Berlin SSRI zur Behandlung neuronaler Krankheiten
WO2013014263A1 (fr) * 2011-07-28 2013-01-31 Pierre Fabre Medicament Medicament a base de levomilnacipran pour la rehabilitation fonctionnelle apres accident neurologique aigu

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2402650T3 (es) 2005-06-17 2013-05-07 Janssen Alzheimer Immunotherapy Métodos de purificación de anticuerpos anti A beta
TW200846003A (en) * 2007-03-15 2008-12-01 Astellas Pharma Inc Novel prophylactic and/or therapeutic agent for diabetic neuropathy
TW200846002A (en) * 2007-03-15 2008-12-01 Astellas Pharma Inc Novel prophylactic and/or therapeutic agent for diabetic neuropathy
US8153813B2 (en) * 2007-12-20 2012-04-10 Abbott Laboratories Benzothiazole and benzooxazole derivatives and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU670675B2 (en) * 1993-02-10 1996-07-25 Yamanouchi Pharmaceutical Co., Ltd. Morpholine derivative
MXPA05004381A (es) * 2002-10-25 2006-02-10 Collegium Pharmaceutical Inc Estereoisomeros de para-hidroxi-milnacipran y metodos de uso de los mismos.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006006617A1 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007051090A1 (de) * 2007-06-28 2009-01-08 Charité - Universitätsmedizin Berlin SSRI zur Behandlung neuronaler Krankheiten
WO2013014263A1 (fr) * 2011-07-28 2013-01-31 Pierre Fabre Medicament Medicament a base de levomilnacipran pour la rehabilitation fonctionnelle apres accident neurologique aigu
FR2978350A1 (fr) * 2011-07-28 2013-02-01 Pf Medicament Medicament a base de levomilnacipran pour la rehabilitation fonctionnelle apres accident neurologique aigu

Also Published As

Publication number Publication date
BRPI0513222A (pt) 2008-04-29
RU2007105494A (ru) 2008-09-10
WO2006006617A1 (ja) 2006-01-19
JPWO2006006617A1 (ja) 2008-04-24
CN1984681A (zh) 2007-06-20
AU2005260955A1 (en) 2006-01-19
NO20070831L (no) 2007-02-13
CA2573611A1 (en) 2006-01-19
ZA200700711B (en) 2008-07-30
US20070259865A1 (en) 2007-11-08
IL180379A0 (en) 2007-06-03

Similar Documents

Publication Publication Date Title
CN102512406B (zh) 用于治疗认知障碍的α-氨基酰胺衍生物
US10537566B2 (en) Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis
EP1767217A1 (de) Wirkstoff zur förderung der erholung von einer dysfunktion nach ausbruch einer erkrankung des zentralen nervensystems
EP3013342B1 (de) Adrenorezeptor-antagonisten zur vorbeugung und behandlung neurodegenerativer erkrankungen
KR20190049905A (ko) 근위축성 측색경화증의 치료 또는 병세 진전 억제를 위한 약제
US6268396B1 (en) Use of valproic acid analog for the treatment and prevention of migraine and affective illness
US20220401456A1 (en) Methods and compositions for treating seizure disorders in pediatric patients
US20220008414A1 (en) Pharmaceutical composition comprising histone deacetylase 6 inhibitors
CN115515590A (zh) 马赛替尼用于治疗多发性硬化患者亚群
CA3153305A1 (en) Methods for treating neurological disorders with ?1a-ar partial agonists
US7816370B2 (en) Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
MX2007000509A (es) Agente para promover la recuperacion de la disfuncion despues del inicio de enfermedad neurologica central.
EP3233825B1 (de) Diarylmethyliden-piperidin-derivate und deren verwendung als delta-opioid-rezeptoragonisten
KR20070032071A (ko) 중추 신경 질환 발증 후의 기능 장해의 회복 촉진제
RU2814327C1 (ru) ПРИМЕНЕНИЕ СУЛЬФАТНЫХ СОЛЕЙ N-(3-(4-(3-(ДИИЗОБУТИЛАМИНО)ПРОПИЛ)ПИПЕРАЗИН-1-ИЛ)ПРОПИЛ)-1Н-БЕНЗО[d]ИМИДАЗОЛ-2-АМИНА И ИХ СОЛЬВАТОВ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ДВИГАТЕЛЬНЫХ НЕЙРОНОВ И НАРУШЕНИЙ НЕРВНО-МЫШЕЧНЫХ СОЕДИНЕНИЙ
WO2022150540A9 (en) Methods and compositions for rapid delivery of anti-seizure therapeutics
JP6738797B2 (ja) レット症候群治療薬
KR20200113345A (ko) 테트라메틸피라진을 포함하는 외상 후 스트레스 장애의 예방 또는 치료용 조성물
Murphy Treatment of Parkinsonism with laevodopa
JP2003525241A (ja) 機能性胃腸疾患治療用トラマドール
WO1998026778A1 (fr) Medicaments pour traiter/prevenir les mouvements anormaux qui accompagnent les troubles du systeme nerveux extrapyramidal

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070111

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20080808